Gabrielle Chappell
@gchappell9
Followers
93
Following
6K
Media
0
Statuses
14
MSc Integrated Immunology DPhil Candidate Molecular and Cellular Medicine Investigating the regulation of NLRP3 in tissue @UniofOxford @KirOxford @JelenaLab
Oxford, UK
Joined July 2021
RT @LakshanieW: Fantastic new work presented by @gchappell9 š¬š§Ŗfrom @JelenaLab about the tissue biology of NLRP3 inflammasome in RA at the @ā¦.
0
7
0
RT @OxImmuno: Brilliant talks in our afternoon session on innate immunity and signalling at #OIS2024 with talks from @JelenaLab, @Boc_Lab,ā¦.
0
4
0
Proud to be part of this work. Congratulations team. @JelenaLab .Emulsion and liposome-based adjuvanted R21 vaccine formulations mediate protection against malaria through distinct immune mechanisms.
cell.com
Reinke, Pantazi, etĀ al. describe two safe open access adjuvants that, in combination with the R21 malaria vaccine, offer strong efficacy in mice. The liposome-based LMQ and squalene emulsion-based SQ...
0
2
16
RT @KirOxford: Our new video is now live! .Click the link below for an insight into what we do here at The Kennedy Institute..
0
10
0
RT @JelenaLab: Soā¦ while I was away for few weeks . my amazing student Anjum won the best Masters Project Prize, and my other amazing studā¦.
0
4
0
C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 āLIVE-AIRā trial
thorax.bmj.com
Objective COVID-19 severity is correlated with granulocyte macrophage colony-stimulating factor (GM-CSF) and C reactive protein (CRP) levels. In the phase three LIVE-AIR trial, lenzilumab an anti-G...
2
6
30
RT @OxBer_MBID: We are happy to announce the poster prize winners of the Oxford-Berlin School on Molecular Basis of Inflammatory Diseases 2ā¦.
0
5
0
RT @LancetRespirMed: NEW ResearchāLenzilumab significantly improved survival without invasive mechanical ventilation in hospitalised patienā¦.
0
62
0